681
Participants
Start Date
August 31, 2006
Primary Completion Date
January 31, 2011
Study Completion Date
October 31, 2013
Ipilimumab
"Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression"
Placebo
Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
Dacarbazine
Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
Local Institution, Hv Amsterdam
Local Institution, Vienna
Local Institution, Buenos Aires
Local Institution, Brussels
Local Institution, Geneva
Local Institution, Saxonworld
Local Institution, Johannesburg
Local Institution, Newcastle
Local Institution, Port Macquarie
Local Institution, Coffs Harbour
Local Institution, Brasschaat
Local Institution, Box Hill
Local Institution, South Brisbane
Local Institution, Port Elizabeth
Local Institution, Kaposyar
Local Institution, Cape Town
Local Institution, Ghent
Memorial Sloan Kettering Cancer Center, New York
Local Institution, Berlin
Local Institution, Marseille
Local Institution, Genova
Local Institution, Cherkassy
St. Luke'S Hospital & Health Network, Bethlehem
Local Institution, Milan
Greater Baltimore Medical Center, Baltimore
Sinai Hospital Of Baltimore, Baltimore
Virginia Cancer Institute, Richmond
Local Institution, Kiel
Blumenthal Cancer Center, Charlotte
Local Institution, Brest
Lowcountry Hematology & Oncology, Pa, Mt. Pleasant
Cancer Specialists Of North Florida Beaches, Jacksonville
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando
Local Institution, Bordeaux
Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie
Local Institution, Padua
Vanderbilt-Ingram Cancer Ctr, Nashville
Thompson Cancer Survival Center, Knoxville
Local Institution, Canarias
Kentucky Cancer Clinic, Hazard
Local Institution, Saint-Etienne
Local Institution, Nantes
Local Institution, Valencia
Central Indiana Cancer Centers, Fishers
Indiana University Cancer Center, Indianapolis
Local Institution, Dnipro
Local Institution, Zaragoza
Local Institution, Siena
Oncology Specialists, Sc, Park Ridge
University Of Chicago, Chicago
Mid-Illinois Hematology/Oncology Associates, Ltd., Normal
Local Institution, Tel Aviv
St Joseph Oncology Inc, Saint Joseph
Ellis Fischel Cancer Center, Columbia
Hutchinson Clinic, Pa, Hutchinson
Local Institution, Mannheim
Local Institution, Heidelberg
Local Institution, Pierre-Bénite
Local Institution, Tübingen
Local Institution, Paris
Local Institution, Lviv
Joe Arrington Cancer Research And Treatment Center, Lubbock
Local Institution, Napoli
Local Institution, München
University Of New Mexico Cancer Center, Albuquerque
Local Institution, Uzhhorod
The Angeles Clinic And Research Institute, Los Angeles
Local Institution, Jerusalem
Wilshire Oncology Medical Group Inc, La Verne
Sharp Clinical Oncology Research, San Diego
Comprehensive Cancer Center, Palm Springs
Pacific Cancer Medical Center, Anaheim
Local Institution, Villejuif
Local Institution, Wurzburg
Local Institution, Ragusa
Providence Portland Medical Center, Portland
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Murmansk
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Stavropol
Local Institution, Pyatigorsk
Local Institution, Ryazan
Local Institution, Samara
Saint Francis Hospital And Medical Center, Hartford
Hematology Oncology, P.C., Stamford
Dana Farber Cancer Institute, Boston
Local Institution, Buenos Aires
Local Institution, Buenos Aires
Local Institution, Córdoba
Local Institution, Santa Fe
Local Institution, Edegem
Local Institution, Fortaleza
Local Institution, Porto Alegre
Local Institution, Porto Alegre, Rs
Local Institution, São Paulo
Local Institution, Edmonton
Local Institution, Montreal
Local Institution, Montreal
Local Institution, Saskatoon
Local Institution, Santiago
Local Institution, Dublin
Local Institution, Galway
Local Institution, Cork
Local Institution, Olomouc
Local Institution, Prague
Local Institution, Jena
Local Institution, Rome
Local Institution, Eindhoven
Local Institution, Montebello
Local Institution, Gdansk
Local Institution, Lodz
Local Institution, Lublin
Local Institution, Poznan
Local Institution, Wroclaw
Local Institution, Lisbon
Local Institution, Groenkloof
Local Institution, Pretoria
Local Institution, Barcelona
Local Institution, Basel
Local Institution, Bristol
Local Institution, Poole
Local Institution, Chelmsford
Local Institution, London
Local Institution, Metropolitan Borough of Wirral
Local Institution, Guildford
Lead Sponsor
Collaborators (1)
Medarex
INDUSTRY
Bristol-Myers Squibb
INDUSTRY